Results 31 to 40 of about 185,056 (259)

Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Antiviral Therapy, 2022
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant.
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi   +4 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

In Vitro Transcribed Artificial Primary MicroRNA for the Inhibition of Hepatitis B Virus Gene Expression in Cultured Cells

Microorganisms
Available interventions for the management of chronic hepatitis B (hepB) exhibit limited efficacy and barriers to vaccination against the hepatitis B virus (HBV) have hampered prophylaxis programmes.
Creanne Shrilall, Patrick Arbuthnot, Abdullah Ely   +2 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Long-term inhibition of Hepatitis B virus gene expression by a primary microrna expressing ancestral adeno-associated viral vector

Virology Journal
Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression cassettes encoding anti-HBV artificial ...
Njabulo Ziphezinhle Mnyandu, Shonisani Wendy Limani, Abdullah Ely, Reubina Wadee, Patrick Arbuthnot, Mohube Betty Maepa   +5 more
doaj   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan

Frontiers in Immunology
IntroductionEmerging Omicron sublineages XBB.1.16 and EG.5.1.1 have caused breakthrough infections, challenging vaccine efficacy. Hybrid immunity—vaccination plus prior SARS-CoV-2 infection—augments neutralizing activity.
Kouki Matsuda, Shohei Yamamoto, Chihiro Motozono, Yoshiki Aritsu, Yuki Furukawa, Airi Noborio, Daisuke Takada, Hiyori Sasagawa, Yuichi Akahori, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Takamasa Ueno, Norio Ohmagari, Tetsuya Mizoue, Kenji Maeda   +14 more
doaj   +1 more source

Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review

Antiviral Therapy, 2023
Background:  Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials.
Ellen Peters, and Collins Iwuji
doaj   +1 more source

Antiviral T‐cell therapy

Immunological Reviews, 2014
SummarySerious viral infections are a common cause of morbidity and mortality after allogeneic stem cell transplantation. They occur in the majority of allograft recipients and are fatal in 17–20%. These severe infections may be prolonged or recurrent and add substantially to the cost, both human and financial, of the procedure.
Leen, Ann M., Heslop, Helen E., Brenner, Malcolm K.   +2 more
openaire   +3 more sources

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source